Plaintiffs who settled a lawsuit with DuPont Chemical over their Washington Works plant near Parkersburg, West Virginia will also be eligible for medical monitoring programs after a three-member science panel analyzed data collected between 2009 and 2011 from nearly 70,000 people. The panel interviewed over 30,000 people, including 28,000 residents and 4,000 workers regarding their medical history.
The science panel concluded their analysis finding a probable link between testicular and kidney cancers and exposure to a chemical used at the DuPont plant. The panel found no link between the chemical C8, perfluorooctanoic acid, and 19 other cancers nor a link between the chemical and adult onset diabetes, Product Design & Development reports.
An attorney for the plaintiffs says that DuPont will spend $235 million on medical monitoring programs in an effort to detect C8 related diseases in residents included in the settlement because of C8 water supply exposure. He also says that members of the class action settlement will now be able to pursue wrongful death and personal injury claims related to C8 exposure.
Currently, DuPont has spent more than $20 million to treat water supplies, and will continue to fund water treatment upgrades, according to the terms of the settlement. DuPont will also discontinue the manufacturing and use of C8 by 2015.